Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).

Cancer

Volumn 120, Issue 19, 2014, Pages 2980-2985

  Philip, Philip A ^a   Goldman, Bryan ^b   Ramanathan, Ramesh K ^b   Lenz, Heinz Josef ^b   Lowy, Andrew M ^b   Whitehead, Robert P ^b   Wakatsuki, Takeru ^b   Iqbal, Syma ^b   Gaur, Rakesh ^b   Benedetti, Jacqueline K ^b   Blanke, Charles D ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI IGF 1R ANTIBODY A12; ANTI-IGF-1R ANTIBODY A12; ANTINEOPLASTIC AGENT; CIXUTUMUMAB; DEOXYCYTIDINE; DRUG DERIVATIVE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; SOMATOMEDIN C;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECT; EGFR; ERLOTINIB SIGNALING; FEMALE; HUMAN; IGF-1R; KAPLAN MEIER METHOD; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PANCREAS CANCER; PANCREAS TUMOR; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED PHASE II; SIGNAL TRANSDUCTION; TARGETED TREATMENT; TREATMENT OUTCOME;

CIXUTUMUMAB; EGFR; ERLOTINIB SIGNALING; IGF-1R; PANCREATIC CANCER; RANDOMIZED PHASE II; TARGETED TREATMENT;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84908500883     PISSN: None     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28744     Document Type: Article

References (0)